Replies to post #13283 on Biotech Values

[DewDiligence]

Re: DNDN, REGN, CEGE

>>DNDN is missing the biotech rally<<

Is that a fair statement? After all, it’s not that long ago that DNDN was in the mid 4’s and now it’s one-third higher at around 6. High volatility is not surprising given the uncertainty about when—and what—the company is going to report for 9902a.

>>I'm puzzled, as REGN is up 50% from my purchase<<

I assumed that REGN was rising on the Lucentis coattails. REGN’s VEGF-Trap is the most similar AMD drug to Lucentis, mechanistically. As you know, REGN just started phase-1 with local administration (#msg-6872397).

I have no idea why CEGE has been strong lately. Regards, Dew